NCT06655883View on ClinicalTrials.gov

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

October 13, 2025

Primary Completion Date

April 15, 2027

Study Completion Date

June 24, 2027

Conditions

Insomnia

Interventions

DRUG

Suvorexant

Oral Tablet

DRUG

Placebo

Oral Tablet

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY